Gross profit increased by 23.9% y-o-y to $15.0 million, with gross profit margin improving 1.7 percentage points y-o-y to 38.4%.
Hyphens Pharma has reported net profit after tax (NPAT) of $3.2 million for the 1QFY2022 ended March, 49.7% higher than net profit of $2.1 million in the same period the year before.
Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments, as well as its newly-acquired subsidiary, Novem.
